Background As the level of consciousness decreases in the dying process, patients lose their ability to swallow and clear oral secretions. As air moves over the secretions, which have pooled in the oropharynx and bronchi, the resulting turbulence produces noisy ventilation with each breath, described as ‘gurgling ‘or ‘rattling noises.’ While there is no evidence that patients find this ‘death rattle’ disturbing, evidence from bereaved surveys suggests the noises can be disturbing to the patient’s visitors and caregivers who may fear that the patient is choking to death. However, similar sounds may occur in patients who are not imminently dying, such as in those with brain injuries or in patients with various disorders leading to increased production or decreased clearance of secretions. Two sub-types of the death rattle have been proposed, although the significance regarding treatment has not been established: Type 1 = predominantly salivary secretions and Type 2 = predominantly bronchial secretions. Death rattle is a good predictor of near death; one study indicated the median time from onset of death rattle to death was 16 hours.
- Position the patient on their side or in a semi-prone position to facilitate postural drainage
- A minute or two of Trendelenburg positioning can be used to move fluids up into the oropharynx for easier removal; aspiration risk is increased, however.
- Gentle oropharyngeal suctioning is used although this can be ineffective when fluids are beyond the reach of the catheter. Frequent suctioning is disturbing to both the patient and the visitors.
- Reduction of fluid intake.
- Communication with family and caregivers aimed to address associated fears and interpretations.
Pharmacological Treatments While multiple studies have questioned the utility of pharmacologic treatments for death rattle, muscarinic receptor blockers (anti-cholinergic drugs) are the most commonly used class of medication for this symptom. Such agents include scopolamine, hyoscyamine, glycopyrrolate, and atropine. All of these agents can cause varying degrees of blurred vision, sedation, confusion, delirium, restlessness, hallucinations, palpitations, constipation, and urinary retention. The primary difference in these drugs is whether they are tertiary amines which cross the blood-brain barrier (scopolamine, atropine, hyoscyamine) or quaternary amines, which do not (glycopyrrolate). Drugs which cross the blood-brain barrier are apt to cause CNS toxicity (sedation, delirium).
- Glycopyrrolate has five times the anti-secretory potency compared to atropine but is poorly and erratically absorbed orally. The clinical significance of this is unclear.
- The scopolamine patch releases ~1 mg over 72 hours. It takes 24 hours to reach steady state and for acute symptoms other drugs should be used. The patch should be placed on hairless skin just behind the ear, is changed every 72 hours, and more than one patch can be used at a time.
- Hyoscyamine is available in short-acting, sustained-released, orally dispersible tablet, and oral solution formulations.
- Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med .2001; 15:329-336.
- Ohio Hospice & Palliative Care Organization. Palliative Care Pocket Consultant. Dubuqe, IA: Kendall Hunt Publishing; 2001.
- Twycross R, Wilcock A, eds. Hospice and Palliative Care Formulary USA. Nottingham, UK: Palliativedrugs.com Ltd; 2006.
- Wilders H, Menten J. Death rattle: prevalence, prevention and treatment. J Pain Symptom Manage. 2002; 23:310-317.
- Wee B, Hillier R. Interventions for noisy breathing in patients near to death. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD005177. DOI: 10.1002/14651858.CD005177.pub2.
- Shimizu Y, Miyashita M, et al. Care strategy for death rattle in terminally ill cancer patients and their family members: recommendations from a cross-sectional nationwide survey of bereaved family members’ perceptions. Journal of pain and symptom management 2014; 48: 2-12.
- Lokker ME, van Zuylen L, et al. Prevalence, impact, and treatment of death rattle: a systematic review. Journal of pain and symptom management 2014;47: 105-122.
Version History: This Fast Fact was originally edited by David E Weissman MD and published in March 2004. 2nd Edition was edited by Drew A Rosielle and published April 2008; 3rd Edition June 2015. Re-copy-edited in April 2009; then again June 2015 with references #6 and #7 added and incorporated into the text.
Fast Facts and Concepts are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual Fast Fact are solely responsible for that Fast Fact’s content. The full set of Fast Facts are available at Palliative Care Network of Wisconsin with contact information, and how to reference Fast Facts.
Copyright: All Fast Facts and Concepts are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright (http://creativecommons.org/licenses/by-nc/4.0/). Fast Facts can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a Fast Fact, let us know!
Disclaimer: Fast Facts and Concepts provide educational information for health care professionals. This information is not medical advice. Fast Facts are not continually updated, and new safety information may emerge after a Fast Fact is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some Fast Facts cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.